PMID- 38279418
OWN - NLM
STAT- MEDLINE
DCOM- 20240129
LR  - 20240206
IS  - 1165-158X (Electronic)
IS  - 0145-5680 (Linking)
VI  - 69
IP  - 14
DP  - 2023 Dec 20
TI  - Bcl-2 expression in cell lines breast cancer and death program.
PG  - 277-285
LID - 10.14715/cmb/2023.69.14.46 [doi]
AB  - Breast cancer is a hormone-dependence and heterogenic disease. Drug resistance is 
      the main reason for the failure of breast cancer treatment. Combinatory 
      medications are methods for treatment but they are not sufficient in action. 
      However, new approaches like molecular therapy reveal a new insight into cancer 
      treatment. Studies show that Bcl-2 gene family inhibitors and ER blockers cause 
      the improvement of recovery. Interfering molecules such as antisense ones can 
      inhibit the expression of Bcl-2 and push the cancer cells to apoptosis. Our team 
      designed a new Antisense Oligonucleotide (ASO) based on Antisense oligo G3139. 
      MCF-7 and MDA-MB-231 cell lines were used to evaluate cellular proliferation. 
      Liposomes and cationic nano-complex (Niosome) are used to increase the cellular 
      delivery of ASO and Tamoxifen. We also investigated the cytotoxicity and 
      apoptotic effects of Tamoxifen, naked ASO and Nano-packed ASO. The results 
      indicated significant down-regulation of the Bcl-2 gene and inhibition of MCF-7 
      and MDA-MB-231 cellular proliferation. Flow-cytometry showed early apoptosis in 
      all cell groups. The newly designed ASO reduced the expression of the Bcl-2 gene. 
      It also had a synergistic effect with the Tamoxifen. The cationic nano-complex 
      (Niosome) was more efficient than the liposome in delivering designed oligo 
      antisense Bcl-2 in the cancer cells.
FAU - Janaghard, Mohsen Sedaghat
AU  - Janaghard MS
AD  - Department of Medical Genetics, School of Advanced Technologies in Medicine, 
      Golestan University of Medical Sciences, Gorgan, Iran. m.sharghi2001@gmail.com.
FAU - Soleimani, Shahrzad
AU  - Soleimani S
AD  - Department of Molecular Genetics, Institute of Basic Science, Shahrekord Islamic 
      Azad University, Iran. movafagh.a@sbmu.ac.ir.
FAU - Movafagh, Abolfazl
AU  - Movafagh A
AD  - Proteomics Research Center, Shahid Beheshti University of Medical Sciences, 
      Tehran, Iran. sar.mousavi1@gmail.com.
FAU - Motallebi, Marzieh
AU  - Motallebi M
AD  - Department Medical Genetics, School of Medicine, Shahid Beheshti University of 
      Medical Sciences. Tehran Iran. saffarmoghadam@goums.ac.ir.
FAU - Mousavi, Seyede Amenh
AU  - Mousavi SA
AD  - Faculty of Science, Islamic Azad University of Ilam, Ilam, Iran. 
      ami.mou449@gmail.com.
FAU - Moghadam, Ali Akbar Saffar
AU  - Moghadam AAS
AD  - Department of Medical Genetics, School of Advanced Technologies in Medicine, 
      Golestan University of Medical Sciences, Gorgan, Iran. 
      saffarmoghadam@goums.ac.ir.
FAU - Moghadam, Vahid Erfani
AU  - Moghadam VE
AD  - Research Center for Stem Cell, Golestan University of Medical Sciences, Gorgan, 
      Iran. sarmosavi@yahoo.com.
FAU - Khosravi, Ayoob
AU  - Khosravi A
AD  - Department of Medical Genetics, School of Advanced Technologies in Medicine, 
      Golestan University of Medical Sciences, Gorgan, Iran. sar.mousavi1@gmail.com.
FAU - Mirzaei, Hamid Reza
AU  - Mirzaei HR
AD  - Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran. saffarmoghadam@goums.ac.ir.
FAU - Mousavi, Seyed Ali Reza
AU  - Mousavi SAR
AD  - Department of Discovery Biology, ADARx Pharmaceuticals Inc. 5871 Oberlin Dr. San 
      Diego, California, United States. sar.mosavi@gmail.com.
FAU - Aziziaram, Zahra
AU  - Aziziaram Z
AD  - Medical Biology Research Center, Kermanshah University of Medical Sciences. 
      zahraaziziaram@gmail.com.
FAU - Sun, Chenghui
AU  - Sun C
AD  - Department of Oncology and Hematology, Houjie Hospital of Dongguan, Dongguan, 
      Guangdong 523962, China. keyan5858@163.com.
LA  - eng
PT  - Journal Article
DEP - 20231220
PL  - France
TA  - Cell Mol Biol (Noisy-le-grand)
JT  - Cellular and molecular biology (Noisy-le-Grand, France)
JID - 9216789
RN  - 0 (Liposomes)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 0 (Oligonucleotides, Antisense)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/metabolism
MH  - Liposomes/pharmacology/therapeutic use
MH  - Proto-Oncogene Proteins c-bcl-2/genetics/metabolism
MH  - Apoptosis/genetics
MH  - Tamoxifen/pharmacology/therapeutic use
MH  - Oligonucleotides, Antisense/genetics/pharmacology
MH  - Cell Line
MH  - Cell Line, Tumor
EDAT- 2024/01/27 12:43
MHDA- 2024/01/29 06:44
CRDT- 2024/01/27 01:02
PHST- 2023/09/28 00:00 [received]
PHST- 2024/01/29 06:44 [medline]
PHST- 2024/01/27 12:43 [pubmed]
PHST- 2024/01/27 01:02 [entrez]
AID - 10.14715/cmb/2023.69.14.46 [doi]
PST - epublish
SO  - Cell Mol Biol (Noisy-le-grand). 2023 Dec 20;69(14):277-285. doi: 
      10.14715/cmb/2023.69.14.46.